Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Codexis revenue
Codexis's revenue is $59.3 million.
What is Codexis's revenue?
- Codexis's revenue growth from 2009 to 2024 is -28.42%.
- Codexis has 165 employees, and the revenue per employee ratio is $359,666.
- Codexis's peak quarterly revenue was $38.4M in 2022(q2).
- Codexis peak revenue was $138.6M in 2022.
- Codexis annual revenue for 2023 was 70.1M, -49.39% growth from 2022.
- Codexis annual revenue for 2024 was 59.3M, -15.39% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Codexis historical revenue
Codexis's peak revenue was $138.6M in 2022. The peak quarterly revenue was $38.4M in 2022(q2).
Codexis's revenue increased from $82.9m in 2009 to $59.3M currently. That's a -28.42% change in annual revenue.
Codexis annual revenue
Codexis annual revenue over time
| Fiscal year / year | Codexis revenue |
|---|---|
| 2009 | $82.9M |
| 2010 | $107.1M |
| 2011 | $123.9M |
| 2012 | $88.3M |
| 2013 | $31.9M |
| 2014 | $35.3M |
| 2015 | $41.8M |
| 2016 | $48.8M |
| 2017 | $50.0M |
| 2018 | $60.6M |
| 2019 | $68.5M |
| 2020 | $69.1M |
| 2021 | $104.8M |
| 2022 | $138.6M |
| 2023 | $70.1M |
| 2024 | $59.3M |
How accurately did Codexis' revenue projections match actual performance?
Codexis annual growth
Codexis saw the greatest revenue growth in 2021, when revenue increased by 51.69%.
Codexis had the lowest revenue growth in 2013, when revenue changed by -63.85%.
Codexis annual growth rate over time
| Year | Codexis growth |
|---|---|
| 2010 | 29%↑ |
| 2011 | 16%↑ |
| 2012 | -29%↓ |
| 2013 | -64%↓ |
| 2014 | 11%↑ |
| 2015 | 18%↑ |
| 2016 | 17%↑ |
| 2017 | 2%↑ |
| 2018 | 21%↑ |
| 2019 | 13%↑ |
| 2020 | 1%↑ |
| 2021 | 52%↑ |
| 2022 | 32%↑ |
| 2023 | -49%↓ |
| 2024 | -15%↓ |
Codexis quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Codexis quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | - | - | - | $24.2M |
| 2010 | $25.7M | $24.5M | $27.1M | $29.8M |
| 2011 | $31.0M | $26.1M | $33.3M | $33.5M |
| 2012 | $31.1M | $22.9M | $26.3M | $7.9M |
| 2013 | $11.5M | $7.0M | $3.9M | $9.5M |
| 2014 | $7.1M | $6.6M | $7.5M | $14.2M |
| 2015 | $6.8M | $6.0M | $17.4M | $11.6M |
| 2016 | $8.0M | $16.0M | $14.9M | $10.0M |
| 2017 | $8.0M | $10.3M | $10.0M | $21.7M |
| 2018 | $14.0M | $13.5M | $16.9M | $16.1M |
| 2019 | $15.6M | $12.3M | $21.9M | $18.7M |
| 2020 | $14.7M | $15.0M | $18.4M | $21.0M |
| 2021 | $18.0M | $25.5M | $36.8M | $24.5M |
| 2022 | $35.3M | $38.4M | $34.5M | $30.4M |
| 2023 | $13.0M | $21.3M | $9.3M | $26.6M |
| 2024 | $17.1M | $8.0M | $12.8M | $21.5M |
Codexis jobs nearby
Do you work at Codexis?
Is Codexis transparent about its revenue structure?
Codexis financial information
| CEO | John J. Nicols |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 165 |
| Date Founded | 2002 |
| Headquarters | Redwood City, California |
| Number of Locations | 1 |
| Revenue | $59.3M |
| Net Income | -$33,592,000 |
| Gross Proft | $43.1M (2024) |
| PE Ratio | -17.97 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.2B |
| Total Assets | $250,393,000 |
| Ticker | CDXS |
Codexis jobs you might like
Codexis financing
Codexis received early financing of $37.0M on 2006-08-14.
| Series | Round size | Date |
|---|---|---|
| Series D | $37M | 08/2006 |
| Post Ipo Equity | $50M | 06/2019 |
| Post Ipo Equity | $75M | 12/2020 |
Codexis investors
| Investors | Security type |
|---|---|
| MAXYGEN INC | Series D |
| Chevron Corporation | Series D |
| EDBI Pte Ltd | Series D |
| CMEA Capital | Series D |
| Pequot Capital | Series D |
| Casdin Capital | Post Ipo Equity |
Codexis competitors
Codexis's top competitor, Merck, earned an annual revenue of $64.2B.
Codexis's smallest competitor is Crown Bioscience with revenue of $12.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Amgen | $93,349 | $33.4B | 22,000 | 726 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Neurocrine Biosciences | $78,232 | $2.4B | 400 | 397 |
| Merck | $90,328 | $64.2B | 74,000 | 1,713 |
| Regeneron | $85,589 | $14.2B | 9,123 | 339 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 744 |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Nektar Therapeutics | $83,561 | $98.4M | 718 | - |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | - |
| Senomyx | $51,255 | $26.4M | 56 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Codexis highest paying jobs
Zippia gives an in-depth look into the details of Codexis, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Codexis. The employee data is based on information from people who have self-reported their past or current employments at Codexis. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Codexis. The data presented on this page does not represent the view of Codexis and its employees or that of Zippia.
Codexis may also be known as or be related to CODEXIS, INC., Codexis, Codexis Inc, Codexis Inc. and Codexis, Inc.